With FALCON-Phase, investigators used PacBio long reads and Hi-C data from Phase Genomics to assemble a haplotype-phased, diploid genome for a hybrid bull.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The company reported first quarter revenues of $19.4 million, missing Wall Street's estimate of $24.5 million.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
Researchers validated 95 percent of structural variants called by PacBio sequencing versus 43 percent with Oxford Nanopore, while Illumina missed thousands.
The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.
The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.
The companies have been embroiled in several lawsuits in the US and in Europe, accusing each other of patent infringement.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.